The AIDS Drug Assistance Program (ADAP) purchase price for the newly approved fixed-dose combination tablet Stribild will be substantially lower than the announced $28,500 wholesale acquisition cost (WAC), as a result of a new pricing agreement reached between Gilead Sciences and the ADAP Crisis Task Force (ACTF). According to a news announcement by the National Alliance of State & Territorial AIDS Directors (NASTAD), the national association that convened ACTF, the agreement also continues a price freeze on all Gilead’s antiretrovirals purchased by ADAPs through 2013. “The fiscal crises many ADAPs continue to experience require ongoing and new commitments on the part of pharmaceutical companies as well as federal and state governments,” explained Dwayne Haught, manager of the Texas ADAP and a founding member of the ACTF.  “We thank Gilead for agreeing to price this new medication for ADAPs at a point that will allow access to it for clients without adversely impacting ADAP budgets.”

To read the NASTAD news announcement, click here.